Zymeworks Inc. (ZYME) surged 30.02% to $24.08, up $5.56, after announcing positive topline results from its Phase 3 HERIZON-GEA-01 trial evaluating Ziihera (zanidatamab-hrii) with chemotherapy, with or without tislelizumab, in first-line treatment of HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma.
Ziihera plus chemotherapy significantly improved progression-free survival compared to the control arm of trastuzumab plus chemotherapy. In the arm with Ziihera plus tislelizumab and chemotherapy, both overall survival and PFS showed statistically significant improvement.
Partner Jazz Pharmaceuticals plans to submit a supplemental Biologics License Application in the first half of 2026, and the company expects the data to be presented at a major medical meeting in early 2026.
On the day of the announcement, ZYME trading volume spiked as the market reacted to the trial success and regulatory implications. The stock's 52-week range is $9.03 - $24.08.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.